Sandoz stock at EUR 75.74 with CHF 30.5 billion market cap

Published on 10/12/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock was at EUR 75.74 at Lang & Schwarz on October 12, 2026. Market capitalization was CHF 30.5 billion on the same date.

Key points in brief

Sandoz stock was at EUR 75.74 at Lang & Schwarz on October 12, 2026 at 2:24 p.m. CEST.
Market capitalization was CHF 30.5 billion, while the 52-week SIX range was CHF 47.73 to CHF 75.90.
First-half 2026 net sales rose 5.00 percent and core EBITDA margin reached 20.90 percent.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz stock (ISIN CH1243598427) was at EUR 75.74 at Lang & Schwarz on October 12, 2026 at 2:24 p.m. CEST, placing the euro quote below the 52-week high of CHF 75.90 on the SIX reference market. The market capitalization was CHF 30.5 billion at the latest finance snapshot.

Price sits below yearly high

The current euro quote leaves Sandoz 0.21 CHF below the 52-week high in the Swiss listing currency, while the 52-week low stands at CHF 47.73. The range shows that the stock is trading much closer to its yearly peak than to its low, but the euro quote and the Swiss franc range are separate market references.

Finanz und Wirtschaft identifies Sandoz with the ticker SDZ, the SIX Swiss Exchange and ISIN CH1243598427. The company is classified in pharmaceuticals, cosmetics and medical products, with generic medicines and biosimilars at the center of its business.

Growth comes from biosimilars

In the first half of 2026, Sandoz increased net sales by 5.00 percent at constant currencies, while biosimilar sales grew 20.00 percent. The company said biosimilars represented 33.00 percent of first-half net sales, and core EBITDA margin expanded by 0.90 percentage points to 20.90 percent, according to Yahoo Finance on August 5, 2026.

The figures put the current valuation in a mixed frame: revenue and biosimilar growth are positive, while investors are also paying attention to the margin profile and the companys exposure to price erosion. The first-half margin improvement provides a concrete operating comparison for the current market value.

Analyst target remains lower

On October 6, 2026, Morgan Stanley analyst Thibault Boutherin raised the Sandoz price target from CHF 55.00 to CHF 60.00 and kept an Underweight rating, as reported by Markets Insider. Barclays maintained a Buy rating and a CHF 93.00 target in a separate October report, according to the same outlet page.

Comparison with peers

Sandoz: P/E 56.8, market capitalization CHF 30.5 billion

Teva Pharmaceutical Industries (USD): plus 4.7 percent, P/E 68.4, market capitalization USD 47.9 billion

Viatris (USD): plus 1.2 percent, P/E minus 49.0, dividend yield 3.0 percent, market capitalization USD 20.5 billion

Market level and trading context

The Sandoz quote at Lang & Schwarz was EUR 75.74 on October 12, 2026 at 2:24 p.m. CEST. The SIX quote was CHF 70.48 at 2:13 p.m. CEST on the same date, while the market capitalization was CHF 30.5 billion.

The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.